

# SAFEGUARDS

## CONSUMER GOODS AND RETAIL

ELECTRICAL & ELECTRONICS

NO. 205/13 NOVEMBER 2013

## EUROPEAN PARLIAMENT BANS HAZARDOUS CHEMICALS IN MEDICAL DEVICES

On 22 October 2013 the European Parliament (EP) voted favorably for the European Commission's proposal on Medical Devices that includes a ban on hazardous chemicals in medical devices.

In accordance with the proposal for a regulation<sup>1</sup> of the European Parliament and of the Council on medical devices, and amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 (COM (2012)0542 – C7-0318/2012 – 2012/0266(COD)), the ban applies to chemicals that are CMR<sup>12</sup> 1A and 1 B, or EDCs<sup>13</sup> according to Regulation (EC) No 1272/2008 of CLP<sup>14</sup> and other EU laws<sup>15</sup>, and which are contained in medical devices and come into contact with the body of patients or are used to administer, transport or store medicines, body fluids or other substances, including gases in concentrations above 0.1% by weight.

The use of CMR 1A, 1B and EDC should be phased out within 8 years from the entry into force of this Regulation if the intended use of such

devices includes treatment of children or treatment of pregnant or nursing women, unless the manufacturer can prove that there are no suitable safer substances or devices without these substances. When the manufacturer can prove that there are no suitable safer substances or devices without these substances, these substances shall be labeled on the device itself and/or on the packaging for each unit as devices containing substances according to ISO 15986.

In spite of the above-mentioned EU proposal there are still many laws related to hazardous substances for medical devices, for examples: EU-RoHS, REACH, POPs and Canada phthalate control act, etc whose overview are given in the table on following page.

<sup>1</sup> [Draft European Parliament Legislative Resolution](#)

<sup>2</sup> [Regulation \(EC\) 1272/2008](#)

<sup>3</sup> [ECHA - REACH legislation](#)

<sup>4</sup> [Directive 2011/65/EU](#)

<sup>5</sup> [Proposal for a Council Decision on Persistent Organic Pollutants](#)

<sup>6</sup> [ECHA - Biocidal products - Regulation](#)

<sup>7</sup> [ECHA - Biocidal products - Product types](#)

<sup>8</sup> [DEHP and BPA - Questions & Answers](#)

<sup>9</sup> [European Commission - Medical Devices - Other related policies](#)

<sup>10</sup> [Candidate List of SVHCs for authorisation](#)

<sup>11</sup> [ECHA List of restrictions table](#)

<sup>12</sup> CMR : carcinogenic, mutagenic and toxic to reproduction

<sup>13</sup> EDCs: Endocrine Disrupting Chemicals (EDCs)

<sup>14</sup> CLP: the European Parliament and of the Council of 16 December 2008 on Classification Labeling and Packaging

<sup>15</sup> Directive 67/548/EEC, 1999/45/EC and Regulation 1907/2006

| NAME OF LAW                              | CODE OF LAW   | REQUIREMENTS  |   | SCOPE   | DATE OF ENTRY INTO FORCE                                     |                |              |
|--|---|---|---|---|--|----------------|--------------|
|  |   | HAZARDOUS SUBSTANCES  | THRESHOLDS/ ACTIONS   |   |  |                |              |
| <b>EUROPE</b>                            |   |   |   |   |  |                |              |
| RoHS recast <sup>4</sup>                 | Directive 2011/65/EU  | Lead  | < 0.1%  | electronic medical device excluding active implantable medical devices  | 22 July 2014   |                |              |
|  |   | Cadmium   | < 0.01%   |   |  |                |              |
|  |   | Mercury   | < 0.1%  |   |  |                |              |
|  |   |   |   | Chromium VI   | < 0.1%   | electronic IVD | 22 July 2016 |
|  |   |   |   | PBBs  | < 0.1%   |                |              |
|  |   |   |   | PBDEs   | <0.1%  |                |              |
| REACH                                    | Regulation 1907/2006  | SVHC > 0.1% & SVHC <sup>10</sup> > 1t/y   | Notifying ECHA  | All medical devices   | 1 June 2007  |                |              |
|  |   | SVHC > 0.1%   | Providing information of safe use to acceptors or consumers   |   |  |                |              |
|  |   | Dangerous substances in Annex 17 <sup>11</sup>                                    | prohibited/ restricted  |   |  |                |              |
| POPs <sup>5</sup>                        | Regulation 850/2004; Regulation 757/2010; Regulation 519/2012 | Annex 1   | prohibited/ restricted  | All medical devices   | 20 May 2004  |                |              |
|  |   | Annex 2   | restricted  |   |  |                |              |
| Biocidal Product Regulation <sup>6</sup> | Regulation 528/2012   | Article is treated with biocidal product containing the approved active substance | Providing the consumers with information about the biocidal treatment of the article that is placed on the market | materials under 22 product types <sup>7</sup>   | 1 September 2013   |                |              |
| <b>CANADA</b>                            |   |   |   |   |  |                |              |
| Phthalate control act <sup>9</sup>       | Bill C-307  | Phthalates > 0.1%   | Notifying Health Canada   | All medical devices   | when Bill C-307 is passed; the bill is in the third reading. |                |              |
|  |   | Bisphenol A > 0.1%  | Notifying Health Canada   | The scope is limited to medical device that comes into contact with patient and user's body fluids, tissue and skin |  |                |              |

Besides the laws mentioned in the above table, information about medical device non-chemical EU-laws, such as WEEE, can also be found on European commission's website<sup>9</sup>.

SGS is committed to keeping you up to date on the latest regulations and policies concerning the use of hazardous substances in medical devices. Furthermore, through our expertise and global network of chemical labs, SGS can support you in ensuring your products comply with relevant hazardous substances requirements on all relevant markets around the world.

Whether you are in need of hazardous substances testing or other third party verification, certification or inspection services, SGS is an ideal service provider to satisfy all your business's needs.

[www.sgs.com/en/Consumer-Goods-Retail/Medical-Devices](http://www.sgs.com/en/Consumer-Goods-Retail/Medical-Devices)



---

#### FOR ENQUIRIES:

Global Competence Support Centre:  
[gcsc@sgs.com](mailto:gcsc@sgs.com)

TW—Richie Chang  
Tel: +886 2 22993279 Ext. 3136 or  
[richie.chang@sgs.com](mailto:richie.chang@sgs.com)

Asia – Hong Kong,  
Tel: +852 2334 4481,  
[mktg.hk@sgs.com](mailto:mktg.hk@sgs.com)

Australasia – Perth.  
Tel: +61 (0) 3 9790 3418  
[au.cts@sgs.com](mailto:au.cts@sgs.com)

Europe – London – UK.  
Tel: +44(0) 203 008 7860  
[gb.cts.sales@sgs.com](mailto:gb.cts.sales@sgs.com)

Africa & Middle East – Turkey.  
Tel: +90 212 368 40 00  
[sgs.turkey@sgs.com](mailto:sgs.turkey@sgs.com)

Americas – USA.  
Tel: +1 973 575 5252  
[uscts.inquiries@sgs.com](mailto:uscts.inquiries@sgs.com)

[www.sgs.com/cgmr](http://www.sgs.com/cgmr)

© SGS Group Management SA – 2013 – All rights reserved - SGS is a registered trademark of SGS Group Management SA. This is a publication of SGS, except for 3<sup>rd</sup> parties' contents submitted or licensed for use by SGS. SGS neither endorses nor disapproves said 3<sup>rd</sup> parties contents. This publication is intended to provide technical information and shall not be considered an exhaustive treatment of any subject treated. It is strictly educational and does not replace any legal requirements or applicable regulations. It is not intended to constitute consulting or professional advice. The information contained herein is provided "as is" and SGS does not warrant that it will be error-free or will meet any particular criteria of performance or quality. Do not quote or refer any information herein without SGS's prior written consent.